Functional Self-Similar Polyether-Polyester Mimicking Host Defense Peptides Enable Prolonged Antimicrobial Activity.
Forget short-lived antimicrobial activity. A team from Tongji and Fudan University just took a clever swing at the problem with a new class of polyether-polyester polymers that mimic host defense peptides (HDPs). The kicker: these functional "self-similar" polymers hold their own against bacteria even after being chopped up by enzymes, a common weak spot for most peptide-based antimicrobials.
ACS Macro Lett
by Huang S, Qian Y, Wei J et al.
“Functional Self-Similar Polyether-Polyester Mimicking Host Defense Peptides Enable Prolonged Antimicrobial Activity. Huang S(1), Qian Y(1), Wei J(2), Chen S(1), Zhou C(1). Author information: (1)School of Material Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China. (2)College of Smart Materials and Future Energy, Fudan University, 220 Handan Road, Shanghai 200438, China. Maintaining a potent antimicrobial efficacy over extended periods is critical for treating bacterial infections associated with chronic wounds. Although host defense peptides (HDPs) and their cationic polymer mimics are effective against drug-resistant bacteria, their long-term performance is often compromised by protease-mediated degradation. Herein, we report a series of cationic polyether-polyester-mimicking HDPs exhibiting consistently potent antimicrobial efficacy and excellent biocompatibility in both intact and degraded forms, termed functional self-similar polymers. The optimal copolymer, P8, displayed broad-spectrum antimicrobial activity down to 0.5 μg/mL and retained strong activity after enzymatic degradation (minimum inhibitory concentration of 16 μg/mL). This superior performance arises from the rational design of the copolymer backbone and hydrophobic side chains. Notably, P8 demonstrated potent in vivo antibacterial performance and safety in mice models. These results highlight the design of functional self-similar polymers as a promising strategy to address bacterial resistance and meet the clinical demand for prolonged, low-toxicity antibacterial therapies.”
Why does this matter? Chronic wounds and drug-resistant infections are tough to treat partly because traditional HDPs and their polymer mimics break down fast in the body. Once proteases get to them, game over. The researchers flipped this script. Their star performer, a copolymer called P8, not only wiped out bacteria at impressively low concentrations (as low as 0.5 μg/mL), but even after degradation, it still packed a punch—minimum inhibitory concentration of 16 μg/mL. That’s rare.
What makes these polymers tick:
They're designed with a smart backbone and hydrophobic side chains that stick around after degradation
Both the intact and broken-down forms keep up the fight against bacteria
P8 worked in live mouse models—not just in a petri dish
Biocompatibility looks solid, so the safety profile is promising
The takeaway for peptide researchers: you don’t have to accept rapid breakdown as a fact of life. Smart design, like these self-similar polymers, opens up new ways to extend antimicrobial action in real-world settings.
For anyone deep into peptide research or developing novel antimicrobial materials, this is a clear sign—backbone chemistry and side chain tweaks can make a massive difference. Worth following as these materials move from bench to bedside.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.